KEY CHARACTERISTICS • Manufactured under change control principles beyond CAS number (similar level as MEVOPUR concentrates), reducing risk of change • Free from animal-derived substances and phthalates • Suitable for blown film, injection molding, blow molding and extrusion REGULATORY SUPPORT • Raw materials tested to: - ISO 10993-1 - USP chapters , including Class VI, a requirement for ophthalmic and nasal drugs - European Pharmacopeia 3.1.3/3.1.5 (polyolefin) - USP (polyethylene) - ICH Q3D elemental impurities - USP and USP light transmission • Registered Drug Master File (Type III) • Food contact compliance established with FDA/EU* APPLICATION BULLETIN CARRIER MATERIAL PIGMENT CONTENT/TYPE LIGHT FASTNESS THERMAL STABILITY PRODUCT CODE HDPE 50% TiO2 8 300°C PH00075525 LLDPE 60% TiO2 8 300°C PL00075542 LLDPE 70% TiO2 8 300°C PL00075545 PP 50% TiO2 8 300°C PP00075717 Healthcare use limitations apply—see below.

CORE plastisols offer strength and flexibility while being phthalate-free, providing an alternative for markets and applications affected by strict guidelines.

As a major supplier of additives and colors to the plastics industry, ColorMatrix has, in the course of supporting its customers worldwide, developed best practice guidelines for its products which it provides as a free service.

It is a precise and clean process that produces high- quality seams and adhesive-free assembly.

For brand owners and OEMs to achieve this, they need materials free of surface blooms and ready to stand up to everyday wear and tear.

Information given in this document is provided by ColorMatrix free of charge and in good faith.

Formulations are heavy metal-free and manufactured using state-of-the- art pigment dispersion techniques that improve homogenization and color distribution.

PACKAGING SOLUTIONS Film & Sheet SELECTION GUIDE Anti-block BOPET application (PV back sheet, packaging film, industry film) Sleeve application (PETG) Anti-static Migrating anti-static system Flame retardant Halogen free flame retardant system, transparent, UL94 VTM-0 Light stabilizer Protection for outdoor application (UV 380nm) Protection for screen application (UV 400nm) Matting agent Matting agent Pinning agent Increased conductivity O2 scavenger Content protection against oxygen White masterbatch Blue shade white Standard white Black masterbatch Carbon black Cool black system BOPET STANDARD PRODUCT PORTFOLIO Anti-block Standard anti-block Printable A/B/A PET sheet and film High-transparent and low COF Anti-static A/B/A film or sheet (transparency) A/B/A film or sheet (matte) Impact modifier Improve sheet elongation at low temperature Chain extender IV improver, EU food and FDA approved White masterbatch Standard white Matting agent Surface matting agent APET SHEET PRODUCT PORTFOLIO Slip agent Mainly used for multilayer PE/PP film and composite film Anti-block Pure anti-block can be used in transparent film Contain both anti-block and slip agent for polyolefin film Processing masterbatch Used in blowing and tape casting of PE/PP (liquid) Anti-oxidant Protection of film from degrading while processing Increase reclaimed ingredients in the formula Light stabilizer Protection of content Low precipitation, which is especially suitable for thinner PE products, such as film and spinning Anti-fog Good resistance to cold and hot fog, and suitable for thinner film Anti-static Applicable to multilayer PE/PP film and composite film PO SHEET PRODUCT PORTFOLIO www.avient.com Copyright © 2021, Avient Corporation.

And when they get there, they want devices that move with them and keep the new ‘dimension’ free from distractions.

Patterson added, “We are an asset-light, high-touch business that generates very high free cash flow conversion. 2) Tax adjustments include the net tax benefit/(expense) from one-time income tax items, the set-up or reversal of uncertain tax position reserves and deferred income tax valuation allowance adjustments. 9 Attachment 4 Condensed Consolidated Balance Sheets (Unaudited) March 31, 2021 2020 ASSETS Current assets: Cash and cash equivalents $ 594.5 $ 649.5 Accounts receivable, net 642.2 516.6 Inventories, net 357.0 327.5 Other current assets 122.7 108.5 Total current assets 1,716.4 1,602.1 Property, net 675.5 694.9 Goodwill 1,281.9 1,308.1 Intangible assets, net 973.3 1,008.5 Operating lease assets, net 80.9 80.9 Other non-current assets 181.4 176.0 Total assets $ 4,909.4 $ 4,870.5 LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: Short-term and current portion of long-term debt $ 18.8 $ 18.6 Accounts payable 529.6 471.7 Current operating lease obligations 24.3 25.1 Accrued expenses and other current liabilities 290.9 285.6 Total current liabilities 863.6 801.0 Non-current liabilities: Long-term debt 1,852.7 1,854.0 Pension and other post-retirement benefits 111.3 115.0 Non-current operating lease obligations 56.8 56.0 Other non-current liabilities 303.0 332.8 Total non-current liabilities 2,323.8 2,357.8 SHAREHOLDERS' EQUITY Avient shareholders’ equity 1,707.0 1,697.1 Noncontrolling interest 15.0 14.6 Total equity 1,722.0 1,711.7 Total liabilities and equity $ 4,909.4 $ 4,870.5 10 Attachment 5 Condensed Consolidated Statements of Cash Flows (Unaudited) March 31, 2021 2020 Operating Activities Net income $ 79.7 $ 32.8 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization 36.6 19.9 Accelerated depreciation and amortization 0.5 — Share-based compensation expense 2.7 2.1 Changes in assets and liabilities, net of the effect of acquisitions: Increase in accounts receivable (137.6) (56.9) Increase in inventories (35.1) (13.0) Increase in accounts payable 67.3 44.6 Decrease in pension and other post-retirement benefits (7.1) (3.2) Increase in post-acquisition earnout liabilities — 1.0 Decrease in accrued expenses and other assets and liabilities, net (3.4) (19.1) Payment of post-acquisition date earnout liability — (21.0) Net cash provided (used) by operating activities 3.6 (12.8) Investing activities Capital expenditures (16.5) (11.1) Net proceeds from divestiture — 7.1 Net proceeds (used) provided by other assets (2.0) 5.2 Net cash (used) provided by investing activities (18.5) 1.2 Financing activities Purchase of common shares for treasury (4.2) (13.6) Cash dividends paid (19.5) (15.6) Repayment of long-term debt (2.3) (2.0) Payments of withholding tax on share awards (3.1) (1.3) Equity offering proceeds, net of underwriting discount and issuance costs — 496.3 Payment of acquisition date earnout liability — (32.9) Net cash (used) provided by financing activities (29.1) 430.9 Effect of exchange rate changes on cash (11.0) (3.8) (Decrease) increase in cash and cash equivalents (55.0) 415.5 Cash and cash equivalents at beginning of year 649.5 864.7 Cash and cash equivalents at end of period $ 594.5 $ 1,280.2 11 Attachment 6 Business Segment Operations (Unaudited) Operating income and earnings before interest, taxes, depreciation and amortization (EBITDA) at the segment level does not include: special items as defined in Attachment 3; corporate general and administration costs that are not allocated to segments; intersegment sales and profit eliminations; share-based compensation costs; and certain other items that are not included in the measure of segment profit and loss that is reported to and reviewed by the chief operating decision maker.